Search

everythinglearnresearchcommunity

for

Search:↓

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Certain immune system proteins are important for skin healing but can cause problems if there are too many of them.

Proinflammatory fibroblasts and vascular endothelial cells are key in keloid development.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Immune therapy for cancer can cause hair loss scars in some patients.

ILK is essential for skin development, pigmentation, and healing.

Nutraceutical insulin-sensitizing agents may help treat skin conditions like psoriasis and acne.

A man's gray hair got darker and thicker after using a psoriasis drug.

JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

Chemotherapy and cytokine therapy can cause various skin reactions, including hair loss and hypersensitivity.

Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Plasmatherapy improves immune status in vitiligo patients, especially those with segmental vitiligo.

Targeting mitophagy may help treat alopecia areata by reducing inflammasome activation.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

IL-19 and IL-24 help cells respond to DNA damage and could be targeted for cancer and age-related disease treatments.

Early recognition of symptoms is crucial for treating IPEX syndrome with a stem cell transplant.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Tislelizumab can cause cutaneous lupus erythematosus.